Drug intelligence / Profile preview

MVT-01

Development stage: Preclinical
Lead developer: Mucovax
Modality: Vaccines & Immunotherapeutics
Administration: Mucosal

Overview

MVT-01 is a therapeutic mucosal vaccine candidate being developed by Mucovax (Mucosal Vaccine Technologies) in collaboration with Crozet BioPharma for the treatment of genital herpes caused by Herpes Simplex Virus Type 2 (HSV-2). Utilizing Mucovax's proprietary mucosal vaccine platform, MVT-01 is designed to be administered via a mucosal route to elicit both local mucosal and systemic immune responses. The primary goal of the vaccine is to reduce viral replication, shedding, and the severity of disease symptoms in individuals already infected with HSV-2. The program has received support from the National Institute of Allergy and Infectious Diseases (NIAID) and is currently in the preclinical stage of development.

Other names: Mucovax HSV-2 vaccine

Beyond the preview

Go deeper on MVT-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVT-01.

Explore the full profile